TG THERAPEUTICS INC
NASDAQ: TGTX (TG Therapeutics, Inc.)
Kemas kini terakhir: 5 jam lalu33.58
-1.00 (-2.89%)
| Penutupan Terdahulu | 34.58 |
| Buka | 34.02 |
| Jumlah Dagangan | 1,801,403 |
| Purata Dagangan (3B) | 1,894,493 |
| Modal Pasaran | 5,362,332,160 |
| Harga / Pendapatan (P/E TTM) | 12.12 |
| Harga / Pendapatan (P/E Ke hadapan) | 40.82 |
| Harga / Jualan (P/S) | 10.03 |
| Harga / Buku (P/B) | 9.44 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 May 2026 |
| Margin Keuntungan | 10.13% |
| Margin Operasi (TTM) | 7.13% |
| EPS Cair (TTM) | 0.250 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 90.40% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -96.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 107.29% |
| Nisbah Semasa (MRQ) | 4.02 |
| Aliran Tunai Operasi (OCF TTM) | -61.02 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -87.64 M |
| Pulangan Atas Aset (ROA TTM) | 7.26% |
| Pulangan Atas Ekuiti (ROE TTM) | 19.70% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | TG Therapeutics, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 0.75 |
|
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 9.74% |
| % Dimiliki oleh Institusi | 63.22% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Soleus Capital Management, L.P. | 31 Dec 2025 | 3,139,312 |
| Congress Asset Management Co | 31 Mar 2026 | 2,168,081 |
| Pictet Asset Management Holding Sa | 31 Mar 2026 | 1,747,373 |
| Julat 52 Minggu | ||
| Median | 46.00 (36.99%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| JP Morgan | 02 Feb 2026 | 46.00 (36.99%) | Beli | 29.18 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |